Cargando…
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
BACKGROUND: The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation. METHODS:...
Autores principales: | Xing, Yan, Lin, Nancy U., Maurer, Matthew A., Chen, Huiqin, Mahvash, Armeen, Sahin, Aysegul, Akcakanat, Argun, Li, Yisheng, Abramson, Vandana, Litton, Jennifer, Chavez-MacGregor, Mariana, Valero, Vicente, Piha-Paul, Sarina A., Hong, David, Do, Kim-Anh, Tarco, Emily, Riall, Dianna, Eterovic, Agda Karina, Wulf, Gerburg M., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Winer, Eric, Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612080/ https://www.ncbi.nlm.nih.gov/pubmed/31277699 http://dx.doi.org/10.1186/s13058-019-1154-8 |
Ejemplares similares
-
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020) -
Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations
por: Kingston, Belinda, et al.
Publicado: (2019) -
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022) -
PTEN suppresses tumorigenesis by directly dephosphorylating Akt
por: Bu, Lang, et al.
Publicado: (2021) -
circPTEN suppresses colorectal cancer progression through regulating PTEN/AKT pathway
por: Li, Chen, et al.
Publicado: (2021)